As commercial synthetic biology production gathers speed, there are growing calls for greater regulation, reports Yojana Sharma.

India has a heavy TB burden but has the technological capacity to deal with it. T.V. Padma reports.

More than 6,000 US clinical trials are now conducted overseas, and the number is quietly rising in South America.

Researchers are stepping up efforts to finding new treatments for Chagas disease, with three drug candidates in clinical trials.

The pursuit of an AIDS vaccine has boosted African research and capacity to conduct trials, and encouraged other countries to follow suit.

New vaccines normally take years to reach developing countries, but the WHO hopes it can shorten the time drastically for dengue vaccine.

GAVI's model of giving "more and more money" is unsustainable and unaffordable, say critics.

Priya Shetty explores the tools and partnerships that help the public health community counter the threat of counterfeit medicines.

New TB vaccines are facing a major funding shortfall, says Mićo Tatalović, and some countries seem resistant to accepting a future vaccine.

The Grand Challenges initiative has highlighted science's role in saving lives, but it will take longer to achieve concrete results, Bill Gates admits.

South Africa is using nanotechnology to improve existing tuberculosis drugs. Munyaradzi Makoni looks at a developing country's experience.

A microbicide gel showed promise for the first time this year, but a range of HIV prevention could hit shelves in the next few years.

A successful vaccine trial, new drugs, and improved understanding have given new hope to the HIV/AIDS research community.

Traditional and modern medicine have much to offer each other despite their differences. Priya Shetty assesses an uneasy relationship.

The barriers to mainstream medical approval are great but some traditional treatments are finding new routes to acceptance, finds Yojana Sharma.

As tuberculosis strains that are resistant to all known drugs continue to emerge, scientists are trying new approaches to drug development.

Polio is still with us, and scientists are having to rethink vaccination strategies for developing countries in the hope of eradication.

Developing countries are attractive places to run clinical trials, but in many places ethical oversight falls short.

Big pharma drug companies are striking deals with Asian drug researchers to secure the future of the drug industry.